StonvexLoading…
StonvexStonvexStonvexCore line items from BIOA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-08-04 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $1.77M | $2.77M | $8.99M | $5.92M | $3.86M |
Operating Income | Not available | $-25.38M | $-92.78M | $-64.36M | $-41.22M |
Net Income | Not available | $-22.25M | $-80.61M | $-54.66M | $-21.56M |
EPS (Diluted) | $-0.61 | $-0.52 | $-2.24 | $-1.52 | $-0.96 |
Total Assets | Not available | $397.65M | $294.89M | $305.09M | $322.15M |
Total Liabilities | Not available | $18.53M | $22.84M | $27.63M | $27.37M |
Cash & Equivalents | Not available | $241.78M | $188.89M | $215.57M | $220.33M |
Free Cash Flow OCF − CapEx | Not available | $-24.07M | $-82.35M | $-53.98M | $-37.92M |
Shares Outstanding | Not available | 44.39M | 37.39M | 35.85M | 35.85M |